The First Comprehensive Digital Medication Adherence Program

A program designed to engage and support both patients & transplant teams.

emocha’s Digital Adherence Program remotely engages & supports transplant recipients: resulting in better quality of life, improved clinical metrics, and decreased hospital utilization.

Our Digital Medication Adherence Program

Enrollment & Onboarding

Providers recommend emocha to patients who need support, and the emocha team onboards them. Pharmacists first conduct a Comprehensive Medication Review to identify, analyze, and correct potential medication issues.

Daily Engagement & Support

Patients use emocha’s app to take medication, report any side effects, and ask questions: building adherence habits through daily video check-ins with their emocha coach.

Clinically-led Care Team

Coaches provide daily support through our engagement platform. Adherence barriers are documented and addressed, while side effects — including inhaler technique — are escalated to an emocha nurse. Critical issues are triaged back to the provider and care team.

Financial Incentives

Patients receive a small financial incentive to reward high adherence throughout 90 days of video check-ins. emocha continues to monitor refill rates in the following months and re-engages patients in virtual visits if adherence begins to drop.

Program Opportunities & Value

Increase your center’s number of transplants and improve your ranking and revenue.

By improving your center’s overall clinical outcomes and enabling centers to take on riskier transplants, emocha’s solution will improve your transplant center’s SRTR ranking, ultimately leading to an increased number of transplant recipients on your waitlist. This will help your external communications, increase your visibility, and reinforce your competitive advantage.

Decrease likelihood of graft failure post-transplant.

Patients with early declining adherence have rejection rates that are 250% higher than patients with stable adherence rates, and an estimated 20-35% of medium-term graft failures fail largely due to nonadherence. emocha supports patients at every dose of medication through short video check-ins, confirming that immunosuppressive regimens are taken correctly and at the proper timing intervals.

Amplify care coordination after discharge.

When transplant recipients are discharged, care teams must ensure that they have clarity on which medications should be taken and when — as dose timeliness is a critical aspect of immunosuppressive adherence. Daily check-ins close the loop on care coordination post-discharge, eliminating costly medication training and gaps in care, and helping patients form lasting adherence habits.

Protect a second chance at life for transplant recipients.

Transplant recipients, donors, and care teams all bear the burdens of non-adherence and its implications. emocha’s program helps mitigate poor clinical outcomes, thus better protecting the transplantation process for all involved stakeholders.

Ensure costly medication is taken post-transplant.

Given the investment that health plans put into their transplant members, medication adherence is critical. Yet a significant percentage of patients are non-adherent to their anti-rejection immunosuppressive regimens: 15% – 40% among liver; 15% to 22% among kidney; and 20% among heart.

“By creating a daily connection with our members, this new program helps to improve healthcare for the most vulnerable.”
-Mark Puente, President and CEO of UMHP

Trusted by leading health institutions.

Learn more about implementing emocha for your transplant patients.